Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
Sondak
Vernon K
VK
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. Vernon.Sondak@moffitt.org
Smalley
Keiran
K
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D009154:Mutation; D009362:Neoplasm Metastasis; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics* / Q000378:metabolism
D000970:Antineoplastic Agents; D019009:Proto-Oncogene Proteins c-kit; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf